GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » ROE % Adjusted to Book Value

OGN (Organon) ROE % Adjusted to Book Value : 45.13% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Organon ROE % Adjusted to Book Value?

Organon's ROE % for the quarter that ended in Sep. 2024 was 450.86%. Organon's PB Ratio for the quarter that ended in Sep. 2024 was 9.99. Organon's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was 45.13%.

Organon ROE % Adjusted to Book Value Historical Data

The historical data trend for Organon's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon ROE % Adjusted to Book Value Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - - - Negative Equity Negative Equity

Organon Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity Negative Equity Negative Equity 21.94 45.13

Competitive Comparison of Organon's ROE % Adjusted to Book Value

For the Drug Manufacturers - General subindustry, Organon's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organon's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Organon's ROE % Adjusted to Book Value falls into.


Organon ROE % Adjusted to Book Value Calculation

Organon's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

Organon's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=450.86% / 9.99
=45.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Organon's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Organon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
AMRN SCLX MIRA LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD LSE:GSK TSE:4568 TSE:4519 XTER:BAYN SHSE:600276
Traded in Other Exchanges
OGN:Mexico 1OGN:Italy 7XP:Germany
Address
30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Website
https://www.organon.com
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Executives
Kirke Weaver officer: Gen. Counsel & Corp. Secy. 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco director ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman officer: General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco officer: Corporate Controller 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler officer: Chief Commercial Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita officer: Head of Global Business Svcs 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr. officer: Head of Manufacturing 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione officer: Chief Human Resources Officer 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah director 30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter officer: Hd of Ext. Affairs and ESG 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan officer: Head of Research & Development 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139